Anthem Biosciences is involved in the chemistry and biology sectors, offering services from gene design to manufacturing and commercialization.

Anthem Biosciences

OBiO Tech, Inc. is a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in gene and cell therapy services. The company provides integrated solutions for research and manufacturing in this field, supporting clients with a range of therapeutic modalities.

OBiO Tech, Inc.

Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

Panacea Biotec Limited

Piramal Group is a diversified global conglomerate with business interests across pharmaceuticals, financial services, information services, and real estate. The group has a significant presence in over 30 countries and is committed to Knowledge, Action, Care, and Impact as its core values.

Metric
Company Name	Anthem Biosciences	OBiO Tech, Inc.	Panacea Biotec Limited	Piramal Group
Symbol			PANACEABIO
MSH ID	COM:ANTHEMBIO	COM:OBIO-TECH	COM:PANACEABIOTEC	COM:PIRAMAL
Market	PRIVATE	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare	Consumer Goods, 5. Consumer Services, 7. Financial Services & Finance, 9. Real Estate
Industry	Biotechnology	Biotechnology	Biotechnology	Diversified
Country	IN	CN	IN	IN
Stage
Employee Count			1.79K	2.83K
Website	anthembio.com	obio-tech.com	panaceabiotec.com	piramal.com
LinkedIn				piramalenterprises
Founders

Metric
Market Cap			101.56M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue			66.02M
Revenue (LTM)
Revenue (NTM)
Gross Profit			16.86M
EBITDA			-2.37M
Operating Income			-6.70M
Net Income			-138.13K
EPS			-0.00
Diluted EPS			-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.48
Operating Profit Margin			-0.08
EBITDA Margin			-0.04
Net Profit Margin			-0.00
Return on Equity			-0.00
Return on Assets
Return on Capital Employed

COM:ANTHEMBIO

Anthem Biosciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			105.92
P/B Ratio			1.17
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			3.95
EV Multiple			174.46

Metric
Days Sales Outstanding			55.39
Days Payables Outstanding			291.99
Days Inventory Outstanding			200.38
Operating Cycle			239.94
Cash Conversion Cycle			66.88
Asset Turnover			0.45

Metric
Operating Cash Flow			674.13K
Free Cash Flow			-8.50M
Cash Flow to Debt			3.56
Operating Cash Flow/Sales			0.14
Free Cash Flow Yield

Metric
Cash & Equivalents			16.47M
Accounts Receivable			349.46K
Inventory			21.01M
Goodwill
Debt to Capitalization			0.02
Debt to Assets			0.02
Current Ratio			1.61
Quick Ratio			0.99

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue